	US 11,898,208 B2
	Diagnostic method
Yuk-Ming Dennis Lo, Hong Kong (CN); Kwan Chee Allen Chan, Hong Kong (CN); and Chunming Ding, Hong Kong (CN)
Assigned to The Chinese University of Hong Kong, Hong Kong (CN)
Filed by The Chinese University of Hong Kong, Hong Kong (CN)
Filed on Aug. 29, 2019, as Appl. No. 16/555,609.
Application 16/555,609 is a continuation of application No. 15/162,258, filed on May 23, 2016, granted, now 10,435,754.
Application 15/162,258 is a continuation of application No. 11/861,809, filed on Sep. 26, 2007, granted, now 9,371,566, issued on Aug. 29, 2019.
Claims priority of provisional application 60/847,499, filed on Sep. 27, 2006.
Prior Publication US 2020/0071771 A1, Mar. 5, 2020
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01)]

15 Claims

1. A method for prognostication of hepatocellular carcinoma survival using a biological sample from an individual suffering from hepatocellular carcinoma, the method comprising:

(a) obtaining DNA from the biological sample, wherein the biological sample is selected from the group consisting of blood, plasma, serum, saliva, and urine;

(b) digesting the DNA with one or more methylation-sensitive restriction enzymes, wherein the one or more methylation-sensitive restriction enzymes preferentially cleave DNA sequences when present in an unmethylated state than in a methylated state;

(c) detecting a target sequence in the DNA digested in (b), wherein the target sequence comprises at least one segment of RASSF1A promoter sequence comprising at least two methylation-sensitive restriction enzyme recognition sites; and

(d) prognosticating hepatocellular carcinoma survival based on the level of the target sequence determined in (c).